Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US intergroup phase III trial E2997

Journal of Clinical Oncology

Volumn 25, Issue 7, 2007, Pages 799-804

  Grever, Michael R ^a   Lucas, David M ^a   Dewald, Gordon W ^a   Neuberg, Donna S ^a   Reed, John C ^a   Kitada, Shinichi ^a   Flinn, Ian W ^a   Tallman, Martin S ^a   Appelbaum, Frederick R ^a   Larson, Richard A ^a   Paietta, Elisabeth ^a   Jelinek, Diane F ^a   Gribben, John G ^a   Byrd, John C ^a  

^a 215 Means Hall ^*

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD38 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE ZAP 70; PROTEIN MCL 1; PROTEIN P53; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; X LINKED INHIBITOR OF APOPTOSIS; IMMUNOGLOBULIN HEAVY CHAIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; FEMALE; GENE MUTATION; GENETICS; HAZARD ASSESSMENT; HUMAN; LABORATORY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; APOPTOSIS; CHROMOSOME ABERRATION; CONTROLLED CLINICAL TRIAL; IMMUNOGLOBULIN VARIABLE REGION; MIDDLE AGED; MORTALITY; MUTATION; RANDOMIZED CONTROLLED TRIAL; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD38; APOPTOSIS; CHROMOSOME ABERRATIONS; FEMALE; GENES, P53; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 33947544426     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.3089     Document Type: Article

References (35)

1. Damle RN, Wasil T, Fais F, et al: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-1847, 1999
2. Hamblin TJ, Davis Z, Gardiner A, et al: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854, 1999
3. Rassenti LZ, Huynh L, Toy TL, et al: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351:893-901, 2004
4. Del Principe MI, Del Poeta G, Buccisano F, et al: Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 108:853-861, 2006
5. Crespo M, Bosch F, Villamor N, et al: ZAP-70 expression as a surrogate for immunoglobulinvariable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764-1775, 2003
6. Krober A, Seiler T, Benner A, et al: V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100:1410-1416, 2002
7. Wiestner A, Rosenwald A, Barry TS, et al: ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101:4944-4951, 2003
8. Dohner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000
9. Cordone I, Masi S, Mauro FR, et al: p53 expression in B-cell chronic lymphocytic leukemia: A marker of disease progression and poor prognosis. Blood 91:4342-4349, 1998
10. Dighiero G, Maloum K, Desablens B, et al: Chlorambucil in indolent chronic lymphocytic leukemia: French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 338:1506-1514, 1998
11. Rai KR, Peterson BL, Appelbaum FR, et al: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750-1757, 2000
12. Leporrier M, Chevret S, Cazin B, et al: Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98:2319-2325, 2001
13. Johnson S, Smith AG, Loffler H, et al: Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia: The French Cooperative Group on CLL. Lancet 347:1432-1438, 1996
14. Flinn IW, Jemiai Y, Bennett JM, et al: Fludarabine and cyclophosphamide achieves high complete response rate in patients with previously untreated chronic lymphocytic leukemia: ECOG 1997. Blood 98:2649a, 2001
15. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996
16. Byrd JC, Smith L, Hackbarth ML, et al: Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res 63:36-38, 2003
17. Dohner H, Fischer K, Bentz M, et al: p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580-1589, 1995
18. Byrd JC, Gribben JG, Peterson BL, et al: Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy. J Clin Oncol 24:437-443, 2006
19. Stilgenbauer S, Bullinger L, Lichter P, et al: Genetics of chronic lymphocytic leukemia: Genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia 16:993-1007, 2002
20. Lin K, Sherrington PD, Dennis M, et al: Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 100:1404-1409, 2002
21. Dewald GW, Brockman SR, Paternoster SF, et al: Chromosome anomalies detected by interphase fluorescence in situ hybridization: Correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 121:287-295, 2003
22. Rines RD, van Orsouw NJ, Sigalas I, et al: Comprehensive mutational scanning of the p53 coding region by two-dimensional gene scanning. Carcinogenesis 19:979-984, 1998
23. Mauerer K, Zahrieh D, Gorgun G, et al: Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia. Br J Haematol 129:499-510, 2005
24. Jelinek DF, Tschumper RC, Geyer SM, et al: Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 115:854-861, 2001
25. Kitada S, Andersen J, Akar S, et al: Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses. Blood 91:3379-3389, 1998
26. Wiernik PH, Paietta E, Goloubeva O, et al: Phase II study of theophylline in chronic lymphocytic leukemia: A study of the Eastern Cooperative Oncology Group (E4998). Leukemia 18:1605-1610, 2004
27. Byrd JC, Peterson BL, Morrison VA, et al: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101:6-14, 2003
28. Krober A, Bloehdorn J, Hafner S, et al: Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 24:969-975, 2006
29. Valganon M, Giraldo P, Agirre X, et al: p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV. Br J Haematol 129:53-59, 2005
30. Eichhorst BF, Busch R, Hopfinger G, et al: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885-891, 2006
31. Lozanski G, Heerema NA, Flinn IW, et al: Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103:3278-3281, 2004
32. Byrd JC, Lin TS, Dalton JT, et al: Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109:399-404, 2007
33. Gribben JG: Salvage therapy for chronic lymphocytic leukemia and the role of stem cell transplantation. Hematology (Am Soc Hematol Educ Program) 292-298, 2005
34. Moreno C, Villamor N, Colomer D, et al: Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 23:3433-3438, 2005
35. Binet JL, Caligaris-Cappio F, Catovsky D, et al: Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 107:859-861, 2006